A comparative study of the efficacy of NAXOZOL compared to celecoxib in patients with osteoarthritis
Open Access
- 27 January 2020
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 15 (1) , e0226184
Abstract
Selective cyclooxygenase-2 inhibitors (celecoxib) can minimize the gastrointestinal complications related to non-steroidal anti-inflammatory drug (NSAID) use. NAXOZOL is a new combination formulation designed to provide sequential delivery of a non-enteric-coated, immediate-release esomeprazole strontium tetrahydrate 20 mg mantle followed by an enteric-coated naproxen 500 mg core. However, there have been no studies comparing NAXOZOL to celecoxib with respect to gastrointestinal tract protection and pain relief in patients with osteoarthritis. This study was undertaken to compare the effects of NAXOZOL and celecoxib with respect to gastrointestinal tract protection and pain relief in patients with osteoarthritis. The randomized enrolled patients were divided into two treatment groups: a NAXOZOL group and a celecoxib group. All participants received treatments (NAXOZOL, 500/20 mg (naproxen 500 mg, esomeprazole strontium tetrahydrate 20 mg) twice per day versus celecoxib, 200 mg daily) on a 1:1 allocation basis for 12 weeks. The primary outcome was the Leeds Dyspepsia Questionnaire (LDQ) score used for non-inferiority testing. Secondary outcome measures included the Gastrointestinal Symptom Rating Scale (GSRS) score, Visual Analogue Scale (VAS) score, European Quality of Life-5 dimensions (EQ-5D) scale and the EQ-5D Visual Analogue Scale (EQ VAS). Other outcome measures included the use of supplementary or rescue drugs, and the incidence of adverse events. The baseline-adjusted LDQ scores immediately after 12 weeks of treatment in NAXOZOL group were not inferior to those in celecoxib group. The overall change in the baseline-adjusted GSRS score, VAS score, EQ-5D, and EQ VAS was not different between the two groups. The usage of supplementary drugs and the drug-related incidence of adverse events were not different. However, the days to use rescue drug were longer in celecoxib group than in NAXOZOL group. NAXOZOL was not inferior to celecoxib in protecting the gastrointestinal tract and providing pain relief in patients with osteoarthritis.Keywords
Funding Information
- Hanmi Pharmaceutical Co.,Ltd (HM-IIT-NAX-001)
This publication has 29 references indexed in Scilit:
- Non-steroidal anti-inflammatory drug-induced cardiovascular adverse events: a meta-analysisJournal of Clinical Pharmacy and Therapeutics, 2016
- In brief: Esomeprazole strontium.2014
- Managing the adverse effects of nonsteroidal anti-inflammatory drugsExpert Review of Clinical Pharmacology, 2011
- Long-term safety of naproxen and esomeprazole magnesium fixed-dose combination: phase III study in patients at risk for NSAID-associated gastric ulcersCurrent Medical Research and Opinion, 2011
- Clinical trial: evaluation of gastric acid suppression with three doses of immediate‐release esomeprazole in the fixed‐dose combination of PN 400 (naproxen/esomeprazole magnesium) compared with naproxen 500 mg and enteric‐coated esomeprazole 20 mg: a randomized, open‐label, Phase I study in healthy volunteersAlimentary Pharmacology & Therapeutics, 2010
- EULAR evidence-based recommendations for the diagnosis of knee osteoarthritisAnnals of the Rheumatic Diseases, 2010
- Nonsteroidal Anti-Inflammatory DrugsPhysical Medicine and Rehabilitation Clinics of North America, 2006
- Tolerability and adverse events in clinical trials of celecoxib in osteoarthritis and rheumatoid arthritis: systematic review and meta-analysis of information from company clinical trial reportsArthritis Research & Therapy, 2005
- Quality of life in patients with endoscopy-negative heartburn: reliability and sensitivity of disease-specific instrumentsAmerican Journal of Gastroenterology, 2001
- Gastrointestinal Tolerability of the Selective Cyclooxygenase-2 (COX-2) Inhibitor Rofecoxib Compared With Nonselective COX-1 and COX-2 Inhibitors in OsteoarthritisArchives of internal medicine (1960), 2000